Cyclophosphamide Tablets USP 50 mg Taj Pharma

1. Name of the medicinal product

Cyclophosphamide Tablets USP 50 mg Taj Pharma
Cyclophosphamide Tablets USP 25 mg Taj Pharma

2. Qualitative and quantitative composition

a) Cyclophosphamide Tablets USP 50 mg Taj Pharma
Each sugar coated tablet contains:
Cyclophosphamide USP
Equivalent to Anhydrous Cyclophosphamide …………… 50mg
Excipients                                                                            q.s.
Colours: Titanium dioxide USP

b) Cyclophosphamide Tablets USP 25 mg Taj Pharma
Each sugar coated tablet contains:
Cyclophosphamide USP
Equivalent to Anhydrous Cyclophosphamide ………………..25 mg
Excipients                                                                            q.s.
Colours: Titanium dioxide USP

3. Pharmaceutical form

Each sugar coated Tablet.

White round biconvex sugar coated tablets with a white core.

4. Clinical particulars
4.1 Therapeutic indications

Cyclophosphamide is a cytotoxic drug for the treatment of malignant disease in adults and children. As a single agent, it has successfully produced an objective remission in a wide range of malignant conditions. Cyclophosphamide is also frequently used in combination with other cytotoxic drugs, radiotherapy or surgery.

4.2 Posology and method of administration

Cyclophosphamide Tablets are for oral use.

Cyclophosphamide should only be used by clinicians experienced in the use of cancer chemotherapy. Cyclophosphamide should only be administered where there are facilities for regular monitoring of clinical, biochemical and haematological parameters before, during, and after administration and under the direction of a specialist oncology service.


Dosage must be individualized. Doses and duration of treatment and/or treatment intervals depend on the therapeutic indication, the scheme of a combination therapy, the patient’s general state of health and organ function, and the results of laboratory monitoring (in particular, blood cell monitoring).

The dosage regimen used for most indications is 100 – 300 mg daily as a single or divided dose.

This treatment should be continued until a clear remission or improvement is seen or be interrupted when the extent of leucopenia becomes unacceptable.

In combination with other cytostatics of similar toxicity, a dose reduction or extension of the therapy-free intervals may be necessary.

Activation of cyclophosphamide requires hepatic metabolism; therefore, oral and intravenous administrations are preferred.

Use of hematopoiesis stimulating agents (colony-stimulating factors and erythropoiesis stimulating agents) may be considered to reduce the risk of myelosuppressive complications and/or help facilitate the delivery of the intended dosing.

During or immediately after the administration, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urinary tract toxicity. Therefore, cyclophosphamide should be administered in the morning. See Section 4.4.

Patients with Hepatic Impairment

Severe hepatic impairment may be associated with decreased activation of cyclophosphamide. This may alter the effectiveness of cyclophosphamide treatment and should be considered when selecting the dose and interpreting response to the dose selected.

Patients with Renal Impairment

In patients with renal impairment, particularly in patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites. This may result in increased toxicity and should be considered when determining the dosage in such patients.

Cyclophosphamide and its metabolites are dialyzable, although there may be differences in clearance depending upon the dialysis system being used. In patients requiring dialysis, use of a consistent interval between cyclophosphamide administration and dialysis should be considered. See Section 4.4.


In elderly patients, monitoring for toxicities and the need for dose adjustment should reflect the higher frequency of decreased hepatic, renal, cardiac, or other organ function, and concomitant diseases or other drug therapy in this population.


No specific information. Children have received Cyclophosphamide. No adverse reactions specific to this group have been reported.

Method of Administration

Cyclophosphamide Tablets should be swallowed with sufficient fluid without chewing. The tablets are coated and should not be divided before use.

4.3 Contraindications

Cyclophosphamide is contra-indicated in patients with:

• hypersensitivity to cyclophosphamide or to any of its metabolites.

• acute infections,

• bone-marrow aplasia,

• urinary tract infection

• acute urothelial toxicity from cytotoxic chemotherapy or radiation therapy

• Urinary outflow obstruction.

Cyclophosphamide should not be used in the management of non-malignant disease, except for immunosuppression in life-threatening situations.

Cyclophosphamide is contra-indicated during pregnancy. See section 4.4 and 4.6.

4.4 Special warnings and precautions for use


Anaphylactic Reactions, Cross-sensitivity with Other Alkylating Agents

Anaphylactic reactions including those with fatal outcomes have been reported in association with cyclophosphamide.

Possible cross-sensitivity with other alkylating agents has been reported.

Myelosuppression, Immunosuppression, Infections

Treatment with cyclophosphamide may cause myelosuppression and significant suppression of immune responses.

Cyclophosphamide-induced myelosuppression can cause leukopenia, neutropenia, thrombocytopenia (associated with a higher risk of bleeding events), and anaemia.

Severe immunosuppression has lead to serious, sometimes fatal, infections. Sepsis and septic shock have also been reported. Infections reported with cyclophosphamide include pneumonias, as well as other bacterial, fungal, viral, protozoal, and parasitic infections.

Latent infections can be reactivated. Reactivation has been reported for various bacterial, fungal, viral, protozoal, and parasitic infections.

Infections must be treated appropriately.

Antimicrobial prophylaxis may be indicated in certain cases of neutropenia at the discretion of the managing physician.

In case of neutropenic fever, antibiotics and/or antimycotics must be given.

Cyclophosphamide should be used with caution, if at all, in patients with severe impairment of bone marrow function and in patients with severe immunosuppression.

Unless essential, cyclophosphamide should not be administered to patients with a leukocyte count below 2500 cells/microlitre (cells/ mm3 and/or a platelet count below 50,000 cells/microlitre (cells/mm3).

Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious infection.

In principle, the fall in the peripheral blood cell and thrombocyte count and the time taken to recover may increase with increasing doses of cyclophosphamide.

The nadirs of the reduction in leukocyte count and thrombocyte count are usually reached in weeks 1 and 2 of treatment. The bone marrow recovers relatively quickly, and the levels of peripheral blood cell counts normalize, as a rule, after approximately 20 days.

Severe myelosuppression must be expected particularly in patients pretreated with and/or receiving concomitant chemotherapy and/or radiation therapy.

Close haematological monitoring is required for all patients during treatment.

Urinary Tract and Renal Toxicity

Hemorrhagic cystitis, pyelitis, ureteritis, and haematuria have been reported with cyclophosphamide therapy. Bladder ulceration/necrosis, fibrosis/contracture and secondary cancer may develop.

Urotoxicity may mandate interruption of treatment.

Cystectomy may become necessary due to fibrosis, bleeding, or secondary malignancy.

Cases of urotoxicity with fatal outcomes have been reported.

Urotoxicity can occur with short-term and long-term use of cyclophosphamide. Hemorrhagic cystitis after single doses of cyclophosphamide has been reported.

Past or concomitant radiation or busulfan treatment may increase the risk for cyclophosphamide-induced hemorrhagic cystitis.

Cystitis is, in general, initially abacterial. Secondary bacterial colonization may follow.

Before starting treatment, it is necessary to exclude or correct any urinary tract obstructions. See Section 4.3.

Urinary sediment should be checked regularly for the presence of erythrocytes and other signs of uro/nephrotoxicity.

Cyclophosphamide should be used with caution, if at all, in patients with active urinary tract infections.

Adequate treatment with mesna and/or strong hydration to force dieresis can markedly reduce the frequency and severity of bladder toxicity. It is important to ensure that patients empty the bladder at regular intervals.

Hematuria usually resolves in a few days after cyclophosphamide treatment is stopped, but it may persist.

It is usually necessary to discontinue cyclophosphamide therapy in instances of severe hemorrhagic cystitis.

Cyclophosphamide has also been associated with nephrotoxicity, including renal tubular necrosis.

Hyponatremia associated with increased total body water, acute water intoxication, and a syndrome resembling SIADH (syndrome of inappropriate secretion of antidiuretic hormone) have been reported in association with cyclophosphamide administration. Fatal outcomes have been reported.

Cardiotoxicity, Use in Patients with Cardiac Disease

Myocarditis and myopericarditis, which may be accompanied by significant pericardial effusion and cardiac tamponade, have been reported with cyclophosphamide therapy and have led to severe, sometimes fatal congestive heart failure.

Histopathologic examination has primarily shown hemorrhagic myocarditis. Haemopericardium has occurred secondary to hemorrhagic myocarditis and myocardial necrosis.

Acute cardiac toxicity has been reported with a single dose of less than 2mg/kg cyclophosphamide.

Following exposure to treatment regimens that included cyclophosphamide, supraventricular arrhythmias (including atrial fibrillation and flutter) as well as ventricular arrhythmias (including severe QT prolongation associated with ventricular tachyarrhythmia) have been reported in patients with and without other signs of cardiotoxicity.

The risk of cyclophosphamide cardiotoxicity may be increased for example, following high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment of the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents. See Section 4.5.

Particular caution is necessary in patients with risk factors for cardiotoxicity and in patients with pre-existing cardiac disease.

Pulmonary Toxicity

Pneumonitis and pulmonary fibrosis have been reported during and following treatment with cyclophosphamide. Pulmonary veno-occlusive disease and other forms of pulmonary toxicity have also been reported.

Pulmonary toxicity leading to respiratory failure has been reported.

While the incidence of cyclophosphamide-associated pulmonary toxicity is low, prognosis for affected patients is poor.

Late onset of pneumonitis (greater than 6 months after start of cyclophosphamide) appears to be associated with a particularly high mortality. Pneumonitis may develop even years after treatment with cyclophosphamide.

Acute pulmonary toxicity has been reported after a single cyclophosphamide dose.

Secondary Malignancies

As with all cytotoxic therapy, treatment with cyclophosphamide involves the risk of secondary tumours and their precursors as late sequelae.

The risk of urinary tract cancer as well as the risk of myelodysplastic alterations, partly progressing to acute leukemias, is increased. Other malignancies reported after use of cyclophosphamide or regimens with cyclophosphamide include lymphoma, thyroid cancer, and sarcomas.

In some cases, the second malignancy developed several years after cyclophosphamide treatment had been discontinued. Malignancy has also been reported after in utero exposure.

Veno-occlusive Liver Disease

Veno-occlusive liver disease (VOLD) has been reported in patients receiving cyclophosphamide.

A cytoreductive regimen in preparation for bone marrow transplantation that consists of cyclophosphamide in combination with whole-body irradiation, busulfan, or other agents has been identified (see Section 4.5) as a major risk factor for the development of VOLD. After cytoreductive therapy, the clinical syndrome typically develops 1 to 2 weeks after transplantation and is characterized by sudden weight gain, painful hepatomegaly, ascites, and hyperbilirubinemia/jaundice.

However, VOLD has also been reported to develop gradually in patients receiving long-term low-dose immunosuppressive doses of cyclophosphamide.

As a complication of VOLD, hepatorenal syndrome and multiorgan failure may develop. Fatal outcome of cyclophosphamide-associated VOLD has been reported.

Risk factors predisposing a patient to the development of VOLD with high-dose cytoreductive therapy include:

– preexisting disturbances of hepatic function,

– previous radiation therapy of the abdomen, and a

– low performance score.


Cyclophosphamide is genotoxic and mutagenic, both in somatic and in male and female germ cells. Therefore, women should not become pregnant and men should not father a child during therapy with cyclophosphamide.

Both women and men should wait at least 6 to 12 months after stopping Cyclophosphamide before attempting to conceive or father a child.

Animal data indicate that exposure of oocytes during follicular development may result in a decreased rate of implantations and viable pregnancies, and in an increased risk of malformations. This effect should be considered in case of intended fertilization or pregnancy after discontinuation of cyclophosphamide therapy. The exact duration of follicular development in humans is not known, but may be longer than 12 months.

Sexually active women and men should use effective methods of contraception during these periods of time.

Fertility, see section 4.6.

Impairment of Wound Healing

Cyclophosphamide may interfere with normal wound healing.



Alopecia has been reported and may occur more commonly with increasing doses.

Alopecia may progress to baldness.

The hair can be expected to grow back after treatment with the drug or even during continued drug treatment, though it may be different in texture or colour.

Nausea and Vomiting

Administration of cyclophosphamide may cause nausea and vomiting.

Current guidelines on the use of antiemetics for prevention and amelioration of nausea and vomiting should be considered.

Alcohol consumption may increase cyclophosphamide-induced vomiting and nausea.


Administration of cyclophosphamide may cause stomatitis (oral mucositis).

Current guidelines on measures for prevention and amelioration of stomatitis should be considered.

Paravenous Administration

The cytostatic effect of cyclophosphamide occurs after its activation, which takes place mainly in the liver. Therefore, the risk of tissue injury from accidental paravenous administration is low.

In case of accidental paravenous administration of cyclophosphamide, the infusion should be stopped immediately, the extravascular cyclophosphamide solution should be aspirated with the cannula in place, and other measures should be instituted as appropriate.

Use in Patients with Renal Impairment

In patients with renal impairment, particularly in patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites. This may result in increased toxicity and should be considered when determining the dosage in such patients. See Section 4.2.

Use in Patients with Hepatic Impairment

Severe hepatic impairment may be associated with decreased activation of cyclophosphamide. This may alter the effectiveness of cyclophosphamide treatment and should be considered when selecting the dose and interpreting response to the dose selected.

Use in Adrenalectomized Patients

Patients with adrenal insufficiency may require an increase in corticoid substitution dose when exposed to stress from toxicity due to cytostatics, including cyclophosphamide.

4.5 Interaction with other medicinal products and other forms of interaction

Planned coadministration or sequential administration of other substances or treatments that could increase the likelihood or severity of toxic effects (by means of pharmacodynamic or pharmacokinetic interactions) requires careful individual assessment of the expected benefit and the risks.

Patients receiving such combinations must be monitored closely for signs of toxicity to permit timely intervention. Patients being treated with cyclophosphamide and agents that reduce its activation should be monitored for a potential reduction of therapeutic effectiveness and the need for dose adjustment.

Interactions Affecting the Pharmacokinetics of Cyclophosphamide and its Metabolites

• Reduced activation of cyclophosphamide may alter the effectiveness of cyclophosphamide treatment. Substances that delay activation of cyclophosphamide include:

– Aprepitant

– Bupropion

– Busulfan: Cyclophosphamide clearance has been reported to be reduced and half-life prolonged in patients who receive high-dose cyclophosphamide less than 24 hours after high-dose busulfan.

– Ciprofloxacin: When given prior to the treatment with cyclophosphamide (used for conditioning prior to bone marrow transplantation), ciprofloxacin has been reported to result in a relapse of the underlying disease.

– Chloramphenicol

– Fluconazole

– Itraconazole

– Prasugrel

– Sulfonamides

– Thiotepa: A strong inhibition of cyclophosphamide bioactivation by thiotepa in high-dose chemotherapy regimens has been reported when thiotepa was administered 1 hour prior to cyclophosphamide.

• An increase of the concentration of cytotoxic metabolites may occur with:

– Allopurinol

– Chloral hydrate

– Cimetidine

– Disulfiram

– Glyceraldehyde

– Inducers of human hepatic and extrahepatic microsomal enzymes (e.g., cytochrome P450 enzymes): The potential for hepatic and extrahepatic microsomal enzyme induction must be considered in case of prior or concomitant treatment with substances known to induce an increased activity of such enzymes such as rifampin, phenobarbital, carbamazepine, phenytoin, St. John’s wort, and corticosteroids.

– Protease inhibitors: Concomitant use of protease inhibitors may increase the concentration of cytotoxic metabolites. Use of protease inhibitor-based regimens was found to be associated with a higher incidence of infections and neutropenia in patients receiving cyclophosphamide, doxorubicin, and etoposide (CDE) than use of an NNRTI-based regimen.

• Ondansetron

There have been reports of a pharmacokinetic interaction between ondansetron and high-dose cyclophosphamide resulting in decreased cyclophosphamide AUC.

Pharmacodynamic Interactions and Interactions of Unknown Mechanism Affecting the Use of Cyclophosphamide

Combined or sequential use of cyclophosphamide and other agents with similar toxicities can cause combined (increased) toxic effects.

• Increased hematotoxicity and/or immunosuppression may result from a combined effect of cyclophosphamide and, for example

– ACE inhibitors: ACE inhibitors can cause leukopenia.

– Natalizumab

– Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion.

– Thiazide diuretics

– Zidovudine

– Clozapine

• Increased cardiotoxicity may result from a combined effect of cyclophosphamide and, for example

– Anthracyclines

– Cytarabine

– Pentostatin

– Radiation therapy of the cardiac region

– Trastuzumab

• Increased pulmonary toxicity may result from a combined effect of cyclophosphamide and, for example

– Amiodarone

– G-CSF, GM-CSF (granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor): Reports suggest an increased risk of pulmonary toxicity in patients treated with cytotoxic chemotherapy that includes cyclophosphamide and G-CSF or GMCSF.

• Increased nephrotoxicity may result from a combined effect of cyclophosphamide and, for example

– Amphotericin B

– Indomethacin: Acute water intoxication has been reported with concomitant use of indomethacin.

• Increase in other toxicities

– Azathioprine: Increased risk of hepatotoxicity (liver necrosis)

– Busulfan: Increased incidence of hepatic veno-occlusive disease and mucositis has been reported.

– Protease inhibitors: Increased incidence of mucositis.

Other interactions

• Alcohol

A reduced antitumor activity was observed in tumor-bearing animals during ethanol (alcohol) consumption and concomitant oral low-dose cyclophosphamide medication.

In some patients, alcohol may increase cyclophosphamide-induced vomiting and nausea.

• Etanercept

In patients with Wegener’s granulomatosis, the addition of etanercept to standard treatment, including cyclophosphamide, was associated with a higher incidence of non-cutaneous solid malignancies.

• Metronidazole

Acute encephalopathy has been reported in a patient receiving cyclophosphamide and metronidazole. Causal association is unclear.

In an animal study, the combination of cyclophosphamide with metronidazole was associated with increased cyclophosphamide toxicity.

• Tamoxifen

Concomitant use of tamoxifen and chemotherapy may increase the risk of thromboembolic complications.

Interactions Affecting the Pharmacokinetics and/or Actions of Other Drugs

• Bupropion

Cyclophosphamide metabolism by CYP2B6 may inhibit bupropion metabolism.

• Coumarins

Both increased and decreased warfarin effect have been reported in patients receiving warfarin and cyclophosphamide.

• Cyclosporine

Lower serum concentrations of cyclosporine have been observed in patients receiving a combination of cyclophosphamide and cyclosporine than in patients receiving only cyclosporine. This interaction may result in an increased incidence of graft-versus-host disease.

• Depolarizing muscle relaxants

Cyclophosphamide treatment causes a marked and persistent inhibition of cholinesterase activity. Prolonged apnea may occur with concurrent depolarizing muscle relaxants (e.g., succinylcholine). If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted.

• Digoxin, β-acetyldigoxin

Cytotoxic treatment has been reported to impair intestinal absorption of digoxin and β-acetyldigoxin tablets.

• Vaccines

The immunosuppressive effects of cyclophosphamide can be expected to reduce the response to vaccination. Use of live vaccines may lead to vaccine-induced infection.

• Verapamil

Cytotoxic treatment has been reported to impair intestinal absorption of orally administered verapamil

4.6 Fertility, pregnancy and lactation


Cyclophosphamide is contraindicated in pregnancy (see section 4.3). Cyclophosphamide crosses the placental barrier. Treatment with cyclophosphamide has a genotoxic effect and may cause foetal damage when administered to pregnant women. Both women and men should wait at least 6 to 12 months after stopping Cyclophosphamide before attempting to conceive or father a child.

• Malformations have been reported in children born to mothers treated with cyclophosphamide during the first trimester of pregnancy. However, there are also reports of children without malformations born to women exposed during the first trimester.

• Exposure to cyclophosphamide in utero may cause miscarriage, foetal growth retardation, and foetotoxic effects manifesting in the newborn, including leukopenia, anaemia, pancytopenia, severe bone marrow hypoplasia, and gastroenteritis.

• Animal data suggest that an increased risk of failed pregnancy and malformations may persist after discontinuation of cyclophosphamide as long as oocytes/follicles exist that were exposed to cyclophosphamide during any of their maturation phases. See Section 4.4, Genotoxicity.

• If cyclophosphamide is used during pregnancy, or if the patient becomes pregnant while taking this drug or after treatment (see Section 4.4, Genotoxicity), the patient should be apprised of the potential hazard to a foetus.


Cyclophosphamide is passed into the breast milk. Neutropenia, thrombocytopenia, low hemoglobin, and diarrhoea have been reported in children breast fed by women treated with cyclophosphamide. Women must not breastfeed during treatment with cyclophosphamide.


Cyclophosphamide interferes with oogenesis and spermatogenesis. It may cause sterility in both sexes.

Development of sterility appears to depend on the dose of cyclophosphamide, duration of therapy, and the state of gonadal function at the time of treatment.

Cyclophosphamide-induced sterility may be irreversible in some patients.

Sexually active women and men should use effective methods of contraception during these periods of time.

• Female patients

Amenorrhea, transient or permanent, associated with decreased oestrogen and increased gonadotrophin secretion develops in a significant proportion of women treated with cyclophosphamide.

For older women, in particular, amenorrhea may be permanent.

Oligomenorrhea has also been reported in association with cyclophosphamide treatment.

Girls treated with cyclophosphamide during prepubescence generally develop secondary sexual characteristics normally and have regular menses.

Girls treated with cyclophosphamide during prepubescence subsequently have conceived.

Girls treated with cyclophosphamide who have retained ovarian function after completing treatment are at increased risk of developing premature menopause (cessation of menses before age of 40 years).

• Male patients

Men treated with cyclophosphamide may develop oligospermia or azoospermia, which are normally associated with increased gonadotrophin but normal testosterone secretion.

Sexual potency and libido generally are unimpaired in these patients.

Boys treated with cyclophosphamide during prepubescence may develop secondary sexual characteristics normally, but may have oligospermia or azoospermia.

Some degree of testicular atrophy may occur.

Cyclophosphamide-induced azoospermia is reversible in some patients, though the reversibility may not occur for several years after cessation of therapy.

4.7 Effects on ability to drive and use machines

Patients undergoing treatment with cyclophosphamide may experience undesirable effects (including, e.g., dizziness, blurred vision, visual impairment) which could affect the ability to drive or use machines. The decision to drive or operate machinery should be made on an individual basis.

4.8 Undesirable effects

ADR frequency is based upon the following scale: Very Common (≥1/10); Common (≥1/100 – <1/10), Uncommon (≥1/1,000 – <1/100), Rare (≥1/10,000 – <1/1,000), Very Rare (<1/10,000), Unknown (adverse reactions reported in the post-marketing experience)

System Organ Class Preferred term Frequency
Infections and infestations Infections1



Septic shock




Not Known

Neoplasms benign, malignant and unspecified (incl cycts and polyps) Acute leukemia3

Myelodysplastic syndrome

Secondary tumours

Bladder cancer

Tumour lysis syndrome





Not known

Blood and lymphatic system disorders Myelosuppression 4

Haemolytic uraemic syndrome

Disseminated intravascular coagulation (DIC )


Very common

Very common

Very rare

Not known

Immune system disorders Immunosuppression

Anaphylactic/Anaphylactoid reaction

Hypersensitivity reaction

Very common

Very rare


Endocrine disorders SIADH Rare
Metabolism and nutrition disorders Anorexia



Fluid retention

Blood glucose changes (increase or decrease)



Very rare

Very rare

Not known

Psychiatric disorders Confusion Very rare
Nervous system disorders Dizziness





Very rare



Eye disorders Conjunctivitis

Eye Oedema

Visual impairment

Lacrimation increased

Very Rare

Very Rare


Not known

Ear and labyrinth disorders Deafness


Not known

Not known

Cardiac disorders Ventricular fibrillation

Ventricular tachycardia

Cardiogenic shock

Pericardial effusion

Myocardial infarction

Cardiac failure




Electrocardiogram QT prolonged


Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Vascular disorders Flushing

Pulmonary embolism

Venous thrombosis


Peripheral ischaemia


Not known

Not known

Not known

Not known

Respiratory, thoracic and mediastinal disorders Pulmonary veno-occlusive disease

Acute respiratory distress syndrome (ARDS)

Interstitial Lung Diseases7

Pulmonary hypertension

Pulmonary oedema





Nasal congestion


Oropharyngeal pain

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Gastrointestinal disorders Enterocolitis haemorrhagic

Acute pancreatitis

Mucosal ulceration






Gastrointestinal Haemorrhage




Abdominal pain

Parotid gland inflammation

Very rare

Very rare

Very rare

Very rare

Very rare

Very rare

Very rare

Very rare







Hepatobiliary disorders Hepatic function abnormal

Veno-occlusive disorder





Not known

Not known

Not known

Not known

Skin and subcutaneous tissue disorders Alopecia



Discoloration of the palms, fingernails, soles

Toxic epidermal necrolysis

Stevens Johnson syndrome

Erythema multiforme

Palmar-plantar erythrodysaesthesia

Radiation recall dermatitis

Erythema in irradiated area

Pruritus (including inflammatory itching)




Facial swelling


Very common




Very rare

Very rare

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Not known

Musculoskeletal and connective tissue disorders Rhabdomyolysis


Muscle spasms



Not known

Not known

Not known

Not known

Not known

Renal and urinary disorders Cystitis


Haemorrhagic cystitis


Suburethral bleeding

Oedema of the bladder wall

Interstitial inflammation, fibrosis, and sclerosis of bladder

Renal failure

Blood creatinine increased

Renal tubular necrosis

Renal tubular disorder

Nephropathy toxic

Hemorrhagic ureteritis

Cystitis ulcerative

Bladder contracture

Nephrogenic diabetes insipidus

Atypical urinary bladder epithelial cells

Blood urea nitrogen increased

Very common

Very common



Very rare

Very rare

Very rare

Very rare

Very rare










Pregnancy, puerperium and perinatal conditions Premature labour Not known
Reproductive system and breast disorders Impairment of spermatogenesis

Ovulation disorder





Ovarian Failure


Testicular atrophy

Blood oestrogen decreased

Blood gonadotrophin increased












Congenital, familial and genetic disorders Intra-uterine death

Fetal malformation

Fetal growth retardation

Fetal toxicity (including myelosuppression/gastroenteritis)

Not known

Not known

Not known

Not known

General disorders and administration site conditions Fever


Mucosal inflammation

Chest pain


tablets is sugar coated

Multiorgan failure


Influenza-like illness

General physical deterioration

Very common




Very Rare

Not known

Not known

Not known

Not known

Not known

Investigations Blood lactate hydrogenase increased

C-reactive protein increased

Not known

Not known

1 including other bacterial, fungal, viral, protozoal, parasitic, reactivation of latent infections, including viral hepatitis, tuberculosis, JC virus with progressive multifocal leucoencephalopathy (including fatal outcomes), Pneumocystis jiroveci, herpes zoster, Strongyloides

2 including fatal outcomes

3 including acute myeloid leukemia, acute promyelocytic leukemia

4 manifested as Bone marrow failure, Pancytopenia, Neutropaenia, Agranulocytosis, Granulocytopenia,Thrombocytopaenia (complicated by bleeding), Leukopenia, Anaemia

5 manifested as reversible posterior leukoencephalopathy syndrome, myelopathy, peripheral neuropathy, polyneuropathy,neuralgia, dysesthesia, hypoesthesia, paresthesia, tremor, dysgeusia, hypogeusia,parosmia.

6 manifested as Atrial fibrillation,Supraventricular arrhythmia ,Ventricular arrhythmia, Bradycardia, Tachycardia,Palpitation

7 manifested by pulmonary fibrosis, obliterative bronchiolitis, organizing pneumonia, alveolitis allergic, pneumonitis

Hepatic failure, Hepatic encephalopathy, Ascites, Hepatomegaly, Jaundice, Blood bilirubin increased, Hepatic enzymes increased (ASAT, ALAT, ALP, gamma-GT)

9 persistent

10 manifested by thrombosis, necrosis, phlebitis, inflammation, pain, swelling, erythema.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

4.9 Overdose

Serious consequences of overdosage include manifestations of dose dependent toxicities such as myelosuppression, urotoxicity, cardiotoxicity (including cardiac failure), veno-occlusive hepatic disease, and stomatitis. See Section 4.4.

Patients who received an overdose should be closely monitored for the development of toxicities, and haematotoxicity in particular.

No specific antidote for cyclophosphamide is known.

Cyclophophamide and its metabolites are dialysable. Consider haemodialysis in cases of severe overdose presenting early, particularly in patients with renal impairment

Overdosage should be managed with supportive measures, including appropriate, state-of-the-art treatment for any concurrent infection, myelosuppression, or other toxicity, should it occur.

Cystitis prophylaxis with mesna may be helpful in preventing or limiting urotoxic effects with cyclophosphamide overdose.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Cyclophosphamide has been demonstrated to have a cytostatic effect in many tumour types. The active metabolites of cyclophosphamide are alkylating agents which transfer alkyl groups to DNA during the process of cell division, thus preventing normal synthesis of DNA.

5.2 Pharmacokinetic properties

Cyclophosphamide is well absorbed following an oral dose with a mean half-life of 4-8 hours for both oral and parenteral administration.

It is an inactive pro drug with alkylating metabolites produced by hepatic metabolism, reaching peak levels 4-6 hours after an iv tablets. Hepatic enzymes may be induced. The parent compound binds poorly to plasma protein but the active metabolites are significantly protein-bound. The drug is widely distributed and crosses the blood-brain barrier, the placental barrier and is found in ascites. The metabolites are excreted renally.

5.3 Preclinical safety data

There are no pre-clinical data of relevance to the prescriber which are additional to the information already stated in other sections of the Summary of Product Characteristics.

6. Pharmaceutical particulars
6.1 List of excipients

Tablet: Maize starch, lactose monohydrate, calcium hydrogen phosphate dihydrate, talc, magnesium stearate, gelatine, glycerol (85%).

Coating: Sucrose, titanium dioxide, calcium carbonate, talc, macrogol 35000, silica colloidal anhydrous, povidone, sodium carboxymethylcellulose, polysorbate 20, montan glycol wax.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

36 months.

6.4 Special precautions for storage

Do not store above 25°C.

Store in original container.

6.5 Nature and contents of container

10 tablets in a PVC/aluminium blister strip and 10 blister strips in a box

6.6 Special precautions for disposal and other handling

Cyclophosphamide is a cytotoxic agent. The handling of cyclophosphamide should always be in accordance with current guidelines on safe handling of cytotoxic agents.

The coating of the tablets prevents direct contact of persons handling the tablets with the active substance. To prevent inadvertent exposure of third persons to the active substance, the tablets should not be divided or crushed.

The tablets should not be handled by women who are pregnant or who are breast feeding.

7. Manufactured in India By:
at SURVEY NO.188/1 TO 189/1,190/1 TO 4,

Cyclophosphamide Tablets USP 50 mg Taj Pharma

Package leaflet: Information for the patient

 Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it
  • If you have any further questions, ask your doctor, pharmacist or
  • If you get any side effects, talk to your doctor, pharmacist or This includes any possible side effects not listed in this leaflet. See section 4.
What is in this leaflet
  1. What is and what it is used for
  2. What you need to know before you are given
  3. How to use
  4. Possible side effects
  5. How to store
  6. Contents of the pack and other information
1.  What is and what it is used for

Contains an active substance called cyclophosphamide. Cyclophosphamide is a cytotoxic medicine or anti-cancer medicine. It works by killing cancer cells, this is sometimes called ‘chemotherapy’.

Cyclophosphamide is often used alone or together with other anti-cancer drugs or radiotherapy in the treatment of various cancers. These include:

  • certain types of cancer of the white blood cells (acute lymphoblastic leukemia, chronic lymphocytic leukemia);
  • different forms of lymphomas that affect the immune system (Hodgkin’s disease, non-Hodgkin’s lymphoma and multiple myeloma);
  • ovarian cancer and breast cancer
  • Ewing’s sarcoma (a form of bone cancer)
  • small cell lung cancer;
  • in the treatment of advanced or metastatic tumor of the central nervous (neuroblastoma);

Furthermore, cyclophosphamide is used in preparation for bone marrow transplantation to treat certain types of cancer of the white blood cells (acute lymphoblastic leukemia, chronic myeloid leukemia and acute myeloid leukemia)

Occasionally, some doctors may prescribe cyclophosphamide for other conditions not related to cancer:

  • life threatening autoimmune diseases: severe progressive forms of lupus nephritis (inflammation of the kidney caused by a disease of the immune system) and Wegener’s granulomatosis (a rare form of vasculitis).
2.  What you need to know before you are given You will not be given :
  • if you are allergic to cyclophosphamide or any of its metabolites. An allergic reaction can include shortness of breath, wheezing, rash, itching or swelling of the face and
  • if you currently have any
  • if your bone marrow is not working properly (especially if you have previously had chemotherapy or radiotherapy). You will have blood tests to check how well your bone marrow is
  • if you have a urinary tract infection, which can be recognised as pain when passing urine (cystitis)
  • you have ever had kidney or bladder problems as a result of previous chemotherapy or radiotherapy if you have a condition which decreases your ability to urinate (urinary outflow obstruction).
  • if you are breast-feeding
Warnings and precautions

Talk to your doctor before being given if you:

·      have low blood cell counts
  • have severe infections
  • have liver or kidney problems. Your doctor will check how well your liver and kidneys are working by doing a blood test have had your adrenal glands removed
  • are already having, or have recently had, radiotherapy or chemotherapy;have heart problems or have had radiotherapy in the area of your heart have diabetes
  • have poor general health or are frail are elderly
  • have had surgery less than 10 days

Potentially life threatening allergic reactions (anaphylactic reaction) may occur during treatment with cyclophosphamide.

Cyclophosphamide can have effects on your blood and immune system.

Blood cells are made in your bone marrow. Three different types of blood cell are made:

  • red blood cells, which carry oxygen around your body,
  • white blood cells, which fight infection, and
  • platelets, which help your blood to

After receiving Cyclophosphamide, your blood count of the three types of cells will drop. This is an unavoidable side effect of Cyclophosphamide . Your blood count will reach its lowest level about 5 to 10 days after you start receiving Cyclophosphamide and will stay low until a few days after you finish the course of treatment. Most people recover to a normal blood count within 21 to 28 days. If you have had a lot of chemotherapy in the past, it may take a little longer to return to normal.

You may be more likely to get infections when your blood count drops. Try to avoid close contact with people who have coughs, colds and other infections. Your doctor will treat you with appropriate medicine if they think you have, or are at risk of an infection.

Your doctor will check that the number of red blood cells, white blood cells and platelets is high enough before and during your treatment with Cyclophosphamide . They may need to reduce the amount of medicine you are given or delay your next dose.

Cyclophosphamide can effect with normal wound healing. Keep any cuts clean and dry and check that they are healing normally. It is important to keep your gums healthy, as mouth ulcers and infections can occur. Ask your doctor about it if you are unsure.

Cyclophosphamide can damage the lining of your bladder, causing bleeding into your urine and pain on urination. Your doctor knows this can happen and, if necessary, he or she will give you a medicine called Mesna which will protect your bladder. Mesna can either be given to you as a short tablets, or mixed into the drip solution with your Cyclophosphamide, or as tablets. More information on Mesna can be found in the Patient Information Leaflet for Mesna tablets and Mesna tablets.

Most people being given Cyclophosphamide with Mesna do not develop any problems with their bladder, but your doctor may want to test your urine for the presence of blood using a ‘dipstick’ or microscope.If you notice that you have blood in your urine, you must tell your doctor straight.

Cancer medicines and radiation therapy can increase the risk of you developing other cancers; this can be a number of years after your treatment has stopped. Cyclophosphamide has an increased risk of causing cancer in the area of your bladder.

Cyclophosphamide can cause damage to your heart or affect the rhythm of its beating. This increases with higher doses of cyclophosphamide, if you are being treated with radiation or other chemotherapy medicines or if you are elderly. Your doctor will monitor your heart closely during treatment.

Cyclophosphamide can cause lung problems such as inflammation or scarring in your lungs. This can occur more than six months after your treatment. If you start having difficulty breathing, tell your doctor straight away.

Cyclophosphamide can have life threatening effects on your liver.

If you have sudden weight gain, liver pain and yellowing of the skin or whites of the eyes (jaundice) tell your doctor straight away.

Hair thinning or baldness can occur. Your hair should grow back normally though it may be different in texture or colour.

Cyclophosphamide can make you feel sick or be sick. This can last for about 24 hours after taking Cyclophosphamide. You may need to be given medicines to stop feeling or being sick. Ask your doctor about this.

Other medicines and

Tell your doctor if you are taking, have recently taken or might take any other medicines. In particular, tell them about the following medicines or treatments as they may not work well with Cyclophosphamide:

The following medicines can reduce how effective Cyclophosphamide is:

·      aprepitant (used to prevent being sick)
  • bupropion (an anti-depressant)
  • busulfan, thiotepa (used to treat cancer)
  • ciprofloxacin, chloramphenicol (used to treat bacterial infections)
  • fluconazole, itraconazole (used to treat fungal infections)
  • Prasugrel (used to thin the blood)
  • Sulfonamides, such as sulfadiazine, sulfasalazine, sulfamethoxazole (used to treat bacterial infections
  • ondansetron (used to prevent being sick)

The following medicines can increase the toxicity of Cyclophosphamide:

·      allopurinol (used to treat gout)
  • azathioprine (used to reduce the activity of the immune system)
  • chloral hydrate (used to treat insomnia)
  • cimetidine (used to reduce stomach acid)
  • disulfiram (used to treat alcoholism)
  • glyceraldehyde (used to treat warts)
  • protease inhibitors (used to treat viruses)
  • medicines that increase liver enzymes such as: rifampicin (used to treat bacterial infections), carbamazepine, phenobarbital, phenytoin (used to treat epilepsy), John’s wort (a herbal remedy for mild depression), Corticosteroids (used to treat inflammation)
  • dabrafenib (anti cancer drug)

Medicines that can increase the toxic effects of Cyclophosphamide on your blood cells and immunity:

  • ACE inhibitors (used to treat high blood pressure).
  • natalizumab (used to treat multiple sclerosis)
  • paclitaxel (used to treat cancer)
  • thiazide diuretics such as hydrochlorothiazide or chlortalidone (used to treat high blood pressure or water retention)
  • zidovudine (used to treat viruses).
  • Clozapine (used to treat symptoms of some psychiatric disorders)

Medicines that can increase the toxic effects of Cyclophosphamide on your heart:

  • anthracyclines such as bleomycin, doxorubicin, epirubicin,
  • mitomycin (used to treat cancer)
  • cytarabine , pentostatin, trastuzumab (used to treat cancer)
  • radiation in the area of your heart

Medicines that can increase the toxic effects of Cyclophosphamide on your lungs

  • amiodarone (used to treat irregular heart beat)
  • G-CSF, GM-CSF hormones (used to increase white blood cell numbers after chemotherapy)

Medicines that can increase the toxic effects of Cyclophosphamide on your kidneys

  • amphotericin B (used to treat fungal infections)
  • Indomethacin (used to treat pain and inflammation)

Other medicines that can affect or be affected by Cyclophosphamide includes.

  • metronidazole (used to treat bacterial or protozoal infections)
  • tamoxifen (used to treat breast cancer)
  • bupropion (used to help stop smoking)
  • coumarins such as warfarin (used to thin the blood)
  • cyclosporine (used to reduce the activity of the immune system)
  • succinylcholine (used to relax muscles during medical procedures)
  • digoxin, ß-acetyldigoxin (used to treat heart conditions)
  • vaccines
  • verapamil (used to treat high blood pressure, angina or irregular heart beat)
  • Sulfonylurea derivatives (blood sugar levels may drop, if cyclophosphamide and sulfonylurea derivatives are used concomitantly)
 with food, drink and alcohol

Drinking alcohol can increase the nausea and vomiting caused by Cyclophosphamide.

Grapefruit (fruit or juice) should not be consumed while taking Cyclophosphamide. It can interfere with the usual effect of your medicine and may alter the effectiveness of Cyclophosphamide. Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.


Cyclophosphamide can cause miscarriage or damage your unborn baby.

If you are a woman, you should not get pregnant during treatment with cyclophsphamide or up to 12 months after treatment.

If you are a man, you should take adequate precautions, including use of an effective contraceptive to ensure that you do not father a child during your treatment with cyclophosphamide or up to 6 months after treatment.


Do not breast-feed while being treated with Cyclophosphamide. Ask your doctor for advice.


Cyclophosphamide can affect your ability to have children in the future. Talk to your doctor about cryo-preservation (freezing) of sperm or eggs prior to treatment because of the possibility of irreversible infertility due to therapy with cyclophosphamide. If you are considering becoming parents after the treatment please discuss this with your doctor.

Driving and using machines

Some of the side effects of treatment with Cyclophosphamide might affect your ability to drive and use machines safely. Your doctor will decide if it is safe for you to do so.

3.  How to use

Method of administration

For intravenous use will be given to you by a a doctor or nurse experienced in the used of cancer chemotherapy is given as an tablets and will normally be added to a large bag of fluid and will be slowly injected (infused) directly into your vein. The vein can be in your arm, the back of your hand or a large vein under your collar bone.

Depending on your dose, it will usually take between 30-120 minutes to be given as an infusion. Cyclophosphamide is often given in combination with other anti-cancer medicines or radiotherapy.

The recommended dose

  • Your doctor will decide how much of the medicine you need and when you should be given it.
  • The amount of cyclophosphamide you will be given depends on:
    • the type of illness you have;
    • how big you are (a combination of your height and weight);
    • your general health;
    • whether you are being given other anti-cancer medicines or having

It is advisable to get cyclophosphamide administered in the morning. Before, during and after the administration, it is important that you get adequate amounts of fluid, to avoid potential adverse effects on the urinary tract.

If you notice is working too strong or too weak, talk to your doctor or pharmacist.

Your doctor may need to change the amount of medicine you are given and monitor you more closely if you:

  • have problems with your liver or kidneys;
  • you are
Use in children and adolescent

Cyclophosphamide is also indicated in children. The safety profile of cyclophosphamide in children is similar to that of adults.

If you use more than you should

As cyclophosphamide is given to you under the supervision of your doctor, it is very unlikely that you will receive too much. However, if you experience any side effects after being given cyclophosphamide, tell your doctor immediately or go to Accident and Emergency at your nearest hospital. You may need urgent medical attention.

Symptoms of a cyclophosphamide overdose include the side effects listed below in the ‘Side Effects’ section, but are usually of a more severe nature.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

  1. Possible side effects

Like all medicines, Cyclophosphamide can cause side effects, although not everybody gets them.

Tell your doctor immediately if you experience:

  • Allergic reactions. Signs of these would be shortness of breath, wheezing, increased heart rate, decreased blood pressure (extreme tiredness), rash, itching or swelling of the face and Severe allergic reactions could lead to difficulty in breathing or shock, with a possible fatal outcome (anaphylactic shock, anaphylactic/ anaphylactoid reaction).
  • getting bruises without knocking yourself, or bleeding from your This may be a sign that the platelet levels in your blood are getting too low
  • Severe infection or fever,ulcers in the mouth, coughing, breathlessness, signs of sepsis like fever, rapid breathing, elevated heart rate, confusion and This may be a sign of a lowering of your white blood cell count and antibiotics may be needed to fight infections.
  • being very pale, lethargic and tired. This may be a sign of low red blood cells (anaemia). Usually, no treatment is required, your body will eventually replace the red blood If you are very anaemic, you may need a blood transfusion
  • having blood in your urine, pain while passing urine, or passing less urine
  • severe pain in the chest
  • symptoms like weakness, vision loss, impaired speech, loss of sense of touch

Cyclophosphamide can also cause the following side-effects:

Very common: may affect more than 1 in 10 people

  • Decrease in the number of blood cells (myelosuppression)
  • Decrease in white blood cells which are important in fighting infection (leucopenia, neutropenia)
  • Loss of hair (alopecia)
  • Burning sensations during urination and frequent need to urinate (cystitis).
  • Appearance of blood in the urine (microhaematuria)
  • Fever
  • Suppression of the immune system
Common: may affect up to 1 in 10 people
  • Infections
  • inflammation of mucous membranes (mucositis)
  • blood in the urine and painful voiding (haemorrhagic cystitis)
  • Appearance of blood in the urine (macrohaematuria)
  • abnormal liver function
  • infertility in men
  • chills
  • feeling of weakness
  • generally feeling unwell
  • Decrease in white blood cells and fever (febrile neutropenia)
Uncommon: may affect up to 1 in 100 people
  • Anaemia (a low red blood cell count) that can leave you feeling tired and drowsy
  • have easy bruising caused by thrombocytopenia (low platelet count)
  • Inflammation of the lung (pneumonia)
  • Sepsis
  • Allergic reactions
  • infertility in women (rarely irreversible)
  • chest pain
  • fast heart beat
  • heart problems
  • changes in the results of some blood tests
  • redness of the skin (flush)
  • damage to the nerves which can cause numbness, pin, and weakness (neuropathy)
  • pain in the distribution of a nerve (neuralgia)
  • anorexia
  • deafness
Rare: may affect up to 1 in 1,000 people
  • increased risk of cancer of the white blood cells (acute leukaemia)and some other cancers (bladder cancer, ureter cancer)
  • ineffective production of the myeloid class of blood cells (myelodysplastic syndrome)
  • increase in the release of antidiuretic hormone from the pituitary gland (syndrome of inappropriate antidiuretic hormone secretion). This affects the kidneys causing the low levels of sodium in your blood (hyponatremia) and water retention resulting in swelling of the brain due to too much water in your Signs of this can be headache, changes in personality or behaviour, confusion, drowsiness.
  • changes in heart beat
  • inflammation of the liver
  • rash
  • inflammation of the skin
  • Lack of menstruation (periods)
  • Lack of spermia
  • Dizziness
  • Visual impairment, blurred vision
  • changes in the color of your nails and skin
  • dehydration
  • convulsion
  • bleedings
Very rare: may affect up to 1 in 10,000 people
  • breakup of red blood cells and kidney failure (Hemolytic uremic syndrome)
  • blood clots form throughout the body’s small blood vessels (Disseminated intravascular coagulation)
  • shock
  • complications that can occur after cancer treatment caused by break-down products of dying cancer cells (tumor lysis syndrome)
  • low levels of sodium in your blood (hyponatremia)
  • high blood pressure (hypertension)
  • low blood pressure (hypotension)
  • angina
  • heart attack
  • occlusion of a blood vessel due to a blood clot in the circulatory system, (thromboemboembolism),
  • injury of the lung (acute respiratory distress syndrome)
  • scarring of the lungs which causes shortness of breath (chronic pulmonary interstitial fibrosis)
  • difficulty breathing with wheezing or coughing (bronchospasm)
  • breathlessness (dyspnoea)
  • a condition in which the body or a region of the body is deprived of adequate oxygen supply (hypoxia)
  • cough
  • soreness or ulcers in the mouth (stomatitis)
  • feeling sick (nausea) being sick (vomiting) or diarrhea
  • constipation
  • inflammation of the intestine
  • inflammation of the pancreas
  • blood clot in the liver (veno-occlusive liver disease)
  • enlargement of the liver (hepatomegaly)
  • yellow eyes or skin
  • severe hypersensitivity reactions with (high) fever, red spots on the skin, joint pain and / or eye infection (Stevens-Johnson syndrome)
  • severe sudden (hypersensitive) reaction with fever and blisters on the skin / peeling of the skin (toxic epidermal necrolysis)
  • Radiation erythaema
  • itching
  • impairment of the sense of taste (dysgeusia, hypogeusia)
  • sensation of tingling, tickling, prickling, pricking, or burning (paraesthesia)
  • impairment of the sense of smell (parosmia)
  • abnormal muscle breakdown which can lead to kidney problems (rhabdomyolysis)
  • cramps
  • problems with your bladder
  • kidney problems, including kidney
  • Headache
  • Multi organ failure
  • tablets reactions
  • Weight gain
  • Confusion
  • Conjunctivitis, eye oedema
  • acute kidney failure with decreased number of red blood cells and platelets (Haemolytic uraemic syndrome)
  • respiratory failure due to fluid accumulation in the lung (pulmonary oedema)
  • accumulation of fluid in the abdominal cavity (ascites)
Not known: frequency cannot be estimated from the available data
  • Different kinds of cancer g. blood cancer (Non-Hodgkin’s lymphoma), kidney cancer, thyroid cancer
  • Sarcoma
  • Different kind of blood disorders (Agranulocytosis, Lymphopenia, Haemoglobin decreased)
  • occlusion of a blood vessel due to a blood clot in the circulatory system, (thromboembolic events), including the possibility of occlusion of the lung vessels (pulmonary embolism)
  • lacrimation increased
  • tinnitus
  • blockage of the nasal passages (nasal congestion)
  • Oropharyngeal pain
  • Rhino rhea
  • Sneezing
  • Pulmonary veno-occlusive disease
  • Obliterative bronchiolitis
  • Alveolitis allergic
  • Pneumonitis
  • Pleural effusion
  • abdominal pain
  • bleeding in stomach or guts
  • intestinal problems/bleeding
  • liver impairment
  • rash, skin reddening, blistering of lips, eyes or mouth, skin peeling (erythema multiforme, urticaria, erythema)
  • hand-foot syndrome
  • facial swelling
  • increased sweating
  • hardening of skin (scleroderma)
  • muscle spasm and pain
  • joint pain
  • inflammation, scarring and contraction of your bladder
  • damage or death of the foetus
  • changes in the results of some blood tests (glucose level, hormone levels)
  • disorder of the brain (encephalopathy), neurotoxicity manifested as a syndrome characterized by headache, confusion, seizures and visual loss (posterior reversible encephalopathy syndrome), abnormal sensation (dysesthesia, hypoesthesia, ), tremor, impairment of the sense of taste (dysgeusia, hypogeusia), impairment of the sense of smell (parosmia)Different kind of heart disorders (Ventricular tachycardia, Cardiogenic shock, Pericardial effusion, Bradycardia, Palpitations, Electrocardiogram QT prolonged)
  • Infertility in women and men
  • Changes in the frequency of menstruation
  • Intra-uterine death
  • Foetal malformation
  • Foetal growth retardation
  • Carcinogenic effect on offspring
  • Salivary gland inflammation (usually in cheek area; parotid gland inflammation)
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Reporting of side effects

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet.

5.  How to store

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label after EXP The expiry date refers to the last day of that month.

Do not store above 25°C.

After reconstitution for intravenous administration

Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C-8°C.

From a microbiological point of view, the reconstituted solution should be used immediately, unless reconstitution has taken place in controlled and validated aseptic conditions. If not used immediately, in-use storage times and conditions before use are the responsibility of the user and would normally not be longer than 24 hours at 2 – 8°C.

Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6.  Contents of the pack and other information

What  contains

  • The active substance is cyclophosphamide 200
What  looks like and contents of the pack

Each 50 mg Cyclophosphamide is sugar coated tablets

7. Manufactured in India By:
at SURVEY NO.188/1 TO 189/1,190/1 TO 4,

Related Products

Taj Generics (Taj Pharma) provides a wide range of products to the Indian market, including an extensive range of generics and specialty products; Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. Our Generics portfolio offers over 1500 products in the major therapeutic areas of gastro-intestinal, cardiovascular, pain management, oncology, anti-infectives, paediatrics and dermatology.